We are live on ! Find out more
DSGN icon

Design Therapeutics

87 hedge funds and large institutions have $77.6M invested in Design Therapeutics in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 38 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

10% less funds holding

Funds holding: 9787 (-10)

10.62% less ownership

Funds ownership: 69.32%58.7% (-11%)

12% less call options, than puts

Call options by funds: $263K | Put options by funds: $299K

29% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 38

42% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 24

68% less capital invested

Capital invested by funds: $244M → $77.6M (-$167M)

Holders
87
Holders Change
-10
Holders Change %
-10.31%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
27
Reduced
38
Closed
24
Calls
$263K
Puts
$299K
Net Calls
-$36K
Net Calls Change
-$12K

DSGN Hedge Fund Activity: Q3 2023 in Review

87 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2023, worth a combined $77.6M — down 68% from $244M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of DSGN and 14 opened new positions — a net loss of 10 holders — while 38 trimmed existing stakes and 27 added.

The largest buyer was Logos Global Management, adding an estimated $10.4M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $32.4M sold.

  • 87 institutional investors held Design Therapeutics (DSGN) as of Q3 2023, down from 97 in Q2 2023.
  • Funds reported $77.6M of Design Therapeutics stock for Q3 2023, down 68% quarter-over-quarter.
  • 14 funds opened new Design Therapeutics positions in Q3 2023 and 24 closed out, a net change of -10 holders.
  • The largest Design Therapeutics buyer in Q3 2023 was Logos Global Management, an estimated $10.4M added.
  • The largest Design Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $32.4M sold.

Based on aggregated 13F filings for Q3 2023.